Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Core Insights - Boundless Bio is advancing its clinical-stage oncology programs, particularly BBI-355, an oral CHK1 inhibitor, with preliminary proof-of-concept data expected in the second half of 2025 [1][2][6] - The company is also progressing a novel Kinesin program aimed at targeting ecDNA segregation, with a development candidate nomination anticipated by mid-2025 and an IND submission planned for the first half of 2026 [1][4][6] Research and Development Highlights - BBI-355 is designed to address replication stress in oncogene-amplified cancers and is currently in a Phase 1/2 POTENTIATE trial [3][6] - The Kinesin program is in preclinical development, focusing on a previously undrugged kinesin essential for ecDNA segregation during cell division [6] Financial Performance - As of December 31, 2024, Boundless Bio reported a cash position of $152.1 million, which is expected to support operations into 2027 [1][7] - Research and Development (R&D) expenses for Q4 2024 were $13.3 million, and for the full year, they totaled $55.3 million, compared to $10.4 million and $42.6 million for the same periods in 2023 [7][8] - General and Administrative (G&A) expenses for Q4 2024 were $5.0 million, with a total of $18.0 million for the full year, up from $3.4 million and $12.2 million in 2023 [7] Corporate Developments - In February 2025, Boundless Bio appointed Robert Doebele, M.D., Ph.D., as Chief Medical Officer, who has extensive experience in oncology program development [4]